Daewoong & Samsung Bioepis’ exclusive sales agreement of Samfenet in Korea
Daewoong Pharmaceutical will jump into the ‘anticancer drug field.’
Daewoong Pharmaceutical announced the company signed an exclusive sales agreement of ‘Samfenet,’ an anticancer biosimilar, in Korea with Samsung Bioepis on the 15th. Under the agreement, the Daewoong Pharmaceutical’s anticancer ...
- $300 per month. ($3,240 per year)
- 5 Email holders per each company.
- Anual contract base.